The pharmacology of anticoagulant drug treatment options in COVID-19 patients: reviewing real-world evidence in clinical practice

References

• Osuchowski MF, Winkler MS, Skirecki T, et al.The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med. 2021;9(6):622–642. Epub 2021 May 6. PMID: 33965003; PMCID: PMC8102044
   Google Scholar
• Russo V, Piccinocchi G, Mandaliti V, et al. Cardiovascular comorbidities and pharmacological treatments of COVID-19 patients not requiring hospitalization. Int J Environ Res Public Health. 2020;18(1):102.
   Google Scholar
• Di Micco P, Camporese G, Russo V, et al. Clinical differences between COVID-19 and a COVID-Like Syndrome. J Clin Med. 2021;10(11):2519.
   Google Scholar
• Russo V, Bottino R, Carbone A, et al.COVID-19 and heart: from clinical features to pharmacological implications. J Clin Med. 2020;9(6):1944. PMID: 32580344; PMCID: PMC7355803
   Google Scholar
• Russo V, Rago A, Carbone A, et al. Atrial Fibrillation in COVID-19: from epidemiological association to pharmacological implications. J Cardiovasc Pharmacol. 2020;76(2):138–145.
   Google Scholar
• Russo V, Di Maio M, Mottola FF, et al. Clinical characteristics and prognosis of hospitalized COVID-19 patients with incident sustained tachyarrhythmias: a multicenter observational study. Eur J Clin Invest. 2020;50(12):e13387. Epub 2020 Sep 17. PMID: 32813877; PMCID: PMC7460920.
   Google Scholar
• Di Micco P, Russo V, Carannante N, et al. Clotting factors in COVID-19: epidemiological association and prognostic values in different clinical presentations in an Italian cohort. J Clin Med. 2020;9(5):1371.
   Google Scholar
• Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46–e47.
   Google Scholar
• Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847.
   Google Scholar
• Di Micco P, Russo V, Carannante N, et al. Prognostic value of fibrinogen among COVID-19 patients admitted to an emergency department: an Italian cohort study. J Clin Med. 2020;9(12):4134.
   Google Scholar
• Scudiero F, Silverio A, Di Maio M, et al. Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome. Thromb Res. 2021;198:34–39.
   Google Scholar
• Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364–374.
   Google Scholar
• Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;75(23):2950–2973.
   Google Scholar
• Di Micco P, Russo V, Lodigiani C. Venous thromboembolism and its association with COVID-19: still an open debate. Medicina (Kaunas). 2020;56(10):506. PMID: 32992511; PMCID: PMC7601141.
   Google Scholar
• Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–1099.
   Google Scholar
• Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023–1026.
   Google Scholar
• Russo V, Di Maio M, Attena E, et al. Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study. Pharmacol Res. 2020;159:104965. Epub 2020 May 29. PMID: 32474087; PMCID: PMC7256617.
   Google Scholar
• Qiu M, Huang S, Luo C, et al. Pharmacological and clinical application of heparin progress: an essential drug for modern medicine. Biomed Pharmacother. 2021;139:111561. Epub 2021 Apr 10. PMID: 33848775.
   Google Scholar
• Di Micco P, Imbalzano E, Russo V, et al. Heparin and SARS-CoV-2: multiple pathophysiological links. Viruses. 2021;13(12):2486.
   Google Scholar
• Canoglu K, Saylan B, Çaliskan T.COVID-19 and thrombosis: prophylaxis and management.Tuberk Toraks.2021;69(2):269–278; English. PMID: 34256519;
   Google Scholar
• Mattioli M, Benfaremo D, Mancini M, et al. Safety of intermediate dose of low molecular weight heparin in COVID-19 patients. J Thromb Thrombolysis. 2020;51:286–292.
   Google Scholar
• Di Micco P, Tufano A, Cardillo G, et al. The impact of risk-adjusted heparin regimens on the outcome of patients with COVID-19 infection. A prospective cohort study. Viruses. 2021;13(9):1720.
   Google Scholar
• Thoreau B, Galland J, Delrue M, et al. D. D-dimer level and neutrophils count as predictive and prognostic factors of pulmonary embolism in severe non-ICU COVID-19 patients. Viruses. 2021;13(5):758. PMID: 33926038; PMCID: PMC8146364.
   Google Scholar
• Morici N, Podda G, Birocchi S, et al. Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: the X-COVID-19 randomized trial. Eur J Clin Invest. 2021;26:e13735. Epub ahead of print. PMID: 34958123.
   Google Scholar
• Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts: onterim guidance. Available online: https://www.scribd.com/document/452851700/WHO-nCov-IPC-HomeCare-2020-3-eng. cited 2022 Mar 20
   Google Scholar
• Lawler PR, Goligher EC, Berger JS, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19. N Engl J Med. 2021;385:790–802.
   Google Scholar
• Sholzberg M, da Costa BR, Tang GH, et al. Randomized trials of therapeutic heparin for COVID-19: a meta-analysis. Res Pract Thromb Haemost. 2021;5(8):e12638. PMID: 34977448; PMCID: PMC8681879.
   Google Scholar
• Houston BL, Lawler PR, Goligher EC, et al. Anti-thrombotic therapy to ameliorate complications of COVID-19 (ATTACC): study design and methodology for an international, adaptive bayesian randomized controlled trial. Clin Trials. 2020;17(5):491–500. Epub 2020 Aug 20. PMID: 32815416.
   Google Scholar
• Angus DC, Berry S, Lewis RJ, et al. The REMAP-CAP (Randomized embedded multifactorial adaptive platform for community-acquired pneumonia) study. Rationale and design. Ann Am Thorac Soc. 2020;17(7):879–891. PMID: 32267771; PMCID: PMC7328186.
   Google Scholar
• Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;181(12):1612. Epub ahead of print. PMID: 34617959.
   Google Scholar
• Zufferey PJ, Dupont A, Lanoiselée J, et al. Pharmacokinetics of enoxaparin in COVID-19 critically ill patients. Thromb Res. 2021;205:120–127. Epub 2021 Jul 21. PMID: 34311154; PMCID: PMC8294601.
   Google Scholar
• REMAP-CAP, Investigators; ACTIV-4a Investigators; ATTACC Investigators, et al. Therapeutic anticoagulation with heparin in critically ill patients with covid-19. N Engl J Med. 2021;385(9):777–789. Epub 2021 Aug 4. PMID: 34351722; PMCID: PMC8362592
   Google Scholar
• Zellmer S, Hanses F, Muzalyova A, et al. Gastrointestinal bleeding and endoscopic findings in critically and non-critically ill patients with Corona virus disease 2019 (COVID-19): results from lean European Open Survey on SARS-CoV-2 (LEOSS) and COKA registries. United European Gastroenterol J. 2021;9(9):1081–1090. Epub 2021 Oct 15. PMID: 34655180; PMCID: PMC8598966.
   Google Scholar
• Imbalzano E, Orlando L, Sciacqua A, et al. Machine learning to calculate heparin dose in COVID-19 patients with active cancer. J Clin Med. 2022;11(1):219.
   Google Scholar
• Demelo-Rodriguez P, Galeano-Valle F, Ordieres-Ortega L, et al. Validation of a prognostic score to identify hospitalized patients with COVID-19 at increased risk for bleeding. Viruses. 2021;13, 2278. DOI:10.3390/v13112278.
   Google Scholar
• Nicolas D, Nicolas S, Hodgens A, et al. Heparin Induced Thrombocytopenia. Available online: https://www.ncbi.nlm.nih.gov/books/NBK482330/. cited 04 August, 2022
   Google Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–352.
   Google Scholar
• Konstantinides SV, Meyer G, Becattini C, et al. The task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J. 2019;54(3):2019.0000000000000893. PMID: 33027192.
   Google Scholar
• Russo V, Cardillo G, Viggiano GV, et al. Fondaparinux use in patients with COVID-19: a preliminary multicenter real-world experience. J Cardiovasc Pharmacol. 2020;76(4):369–371.
   Google Scholar
• Russo V, Cardillo G, Viggiano GV, et al. Thromboprofilaxys with fondaparinux vs. enoxaparin in hospitalized COVID-19 patients: a multicenter Italian observational study. Front Med (Lausanne). 2020;7:569567. PMID: 33330530; PMCID: PMC7729125.
   Google Scholar
• Cardillo G, Viggiano GV, Russo V, et al. Antithrombotic and anti-inflammatory effects of fondaparinux and enoxaparin in hospitalized COVID-19 patients: the FONDENOXAVID Study. J Blood Med. 2021;12:69–75. PMID: 33603528; PMCID: PMC7886238.
   Google Scholar
• Prandoni P, Cattelan AM, Carrozzi L, et al. The hazard of fondaparinux in non-critically ill patients with COVID-19: retrospective controlled study versus enoxaparin. Thromb Res. 2020;196:395–397. Epub ahead of print. PMID: 33007739; PMCID: PMC7497738.
   Google Scholar
• Russo V, Proietti R, Lodigiani C, et al. Fondaparinux and bleeding risk in COVID-19: unsolved question. Thromb Res. 2021;200:128–129. Epub 2021 Feb 9. PMID: 33592530; PMCID: PMC7870442.
   Google Scholar
• Borghi B, Borghi R, Amicis T DE, et al. Early use of fondaparinux at therapeutic dosage in COVID-19 infection. Minerva Anestesiol. 2021;87(8):958–960. Epub 2021 May 7. PMID: 33960182.
   Google Scholar
• Wong AYS, Tomlinson LA, Brown JP, et al. OpenSAFELY Collaborative; Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: population-based cohort study. J Hematol Oncol . 2021;14(1):172.
   Google Scholar
• Ménager P, Brière O, Gautier J, et al. Regular use of VKA prior to COVID-19 associated with lower 7-day survival in hospitalized frail elderly COVID-19 patients: the GERIA-COVID cohort study. Nutrients. 2020;13(1):39.
   Google Scholar
• Rieder M, Gauchel N, Kaier K, et al. Pre-medication with oral anticoagulants is associated with better outcomes in a large multinational COVID-19 cohort with cardiovascular comorbidities. Clin Res Cardiol. 2021;111(3):1–11.
   Google Scholar
• Testa S, Paoletti O, Giorgi-Pierfranceschi M, Pan A. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients. Intern Emerg Med. 2020;15(5):751–753.
   Google Scholar
• Tang Y, Wang X, Li Z, et al. Heparin prevents caspase-11-dependent septic lethality independent of anticoagulant properties. Immunity. 2021;54(3):454–467.
   Google Scholar
• World Health Organization. Living guidance COVID-19 clinical management living guidance; 2021. Available online: https://apps.who.int/iris/handle/10665/338882 cited 2022 Apr 30 **World Health Organization guidence on COVID-19 management
   Google Scholar
• Specialty guides for patient management during the coronavirus pandemic Clinical guide for the management of anticoagulant services during the coronavirus pandemic. NHS England and NHS Improvement; 2021. Available online: https://www.google.com/url? sa=t&source=web&rct=j&url=https://www.nice.org.uk/media/default/about/covid-19/specialty-guides/specialty-guide-anticoagulant-services-and-coronavirus.pdf&ved=2ahUKEwi2muvFzfn5AhUXiv0HHQX4D3MQFnoECA4QAQ&usg=AOvVaw1O9b4YBEbXawLeJhV_Ased. Cited 2022 September 3.
   Google Scholar
  -
   Google Scholar
• Position statement management of patients on oral anticoagulants during COVID_19. Available online at https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.safetyandquality.gov.au/sites/default/files/2020-05/Covid-19%2520-%2520Position%2520statement%2520-%2520Management%2520of%2520patients%2520on%2520oral%2520anticoagulants%2520during%2520COVID-19%2520-%252029%2520April%25202020_0.PDF&ved=2ahUKEwisuLaiz_n5AhWY_rsIHcnzBsoQFnoECBAQAQ&usg=AOvVaw0NXhSOoT1Dv2FuxPSwq39A. Cited 2022 September 3.
   Google Scholar
• The COVID-19 treatment guidelines panel’s statement on anticoagulation in hospitalized patients with COVID-19. Available online: www.covid19treatmentguidelines.nih.gov. cited 2022 May 05.
   Google Scholar
• Russo V, Bottino R, D’Andrea A, et al. Chronic oral anticoagulation and clinical outcome in hospitalized COVID-19 patients. Cardiovasc Drugs Ther. 2021. doi:10.1007/s10557-021-07194-y. •Real world experience showing no benefit on COVID19 disease progression in patients on chronic anticoagulant therapy. •Real world experience showing no benefit on COVID19 disease progression in patients on chronic anticoagulant therapy.
   Google Scholar
• Flam B, Wintzell V, Ludvigsson JF, et al. Direct oral anticoagulant use and risk of severe COVID-19. J Intern Med. 2020;289(3):411–419.
   Google Scholar
• Sivaloganathan H, Ladikou EE, Chevassut T. COVID-19 mortality in patients on anticoagulants and antiplatelet agents. 192-195, s.l. Br J Haematol. 2020;190(4). Doi: 10.1111/bjh.16968
   Google Scholar
• Lewis P, Tharp JL. Breakthrough venous thromboembolic events in five patients with COVID-19 on direct oral anticoagulants 519-523, s.l. J Clin Pharm Ther. 2021;46(2):519–523.
   Google Scholar
• Rossi R, Coppi F, Talarico M, et al. Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era. 158-160, s.l. Eur J Intern Med. 2020;77:158–160.
   Google Scholar
• Denas G, Gennaro N, Ferroni E. Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: a population-based propensity score matched study. 2021. Int J Cardiol. 2021;329:266–269.
   Google Scholar
• COVID-19 rapid guideline: managing COVID-19. s.l.: national Institute for Health and Care Excellence (NICE), 2021. •• National Institute for Health and Care Excellence guidelines for COVID19 treatment. •• National Institute for Health and Care Excellence guidelines for COVID19 treatment
   Google Scholar
• Bill & Melinda Gates Medical Research Institute. Available online: https://clinicaltrials.gov/ct2/show/NCT04504032. Last access 2022 May 05
   Google Scholar
• Connors JM, Maria M, Sciurba FC, et al. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19. JAMA. 2021;326(17):1703–1712.
   Google Scholar
• Cruz, Hospital Alemão Oswaldo. Available online: https://clinicaltrials.gov/ct2/show/NCT04757857. cited 2022 May 06.
   Google Scholar
• Janssen Research & Development, LLC. Available online: https://clinicaltrials.gov/ct2/show/NCT04508023. cited 2022 May 06.
   Google Scholar
• Brazilian Clinical Research Institute. Available online: https://clinicaltrials.gov/ct2/show/NCT04746339. cited 2022 May 06.
   Google Scholar
• Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis, Nopp S, Moik F, Jilma B, et al. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19. Res Pract Thromb Haemost. 2020;4(7):1178–1191.
   Google Scholar
• Klok FA, Kruip MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148–150.
   Google Scholar
• Langella V, Bottino R, Asti A, et al. Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients 1289-1294, s.l. Expert Rev Clin Pharmacol. 2021;14(10):1289–1294.
   Google Scholar
• Cuker A, Tseng EK, Nieuwlaat R, et al. Should DOACs, LMWH, UFH, Fondaparinux, Argatroban, or Bivalirudin at intermediate-intensity or therapeutic-intensity vs. Prophylactic intensity be used for Patients with COVID-19 related critical illness who do not have suspected or confirmed VTE? 2020, ASH 2020 guidelines on the use of anticoagulation in patients with COVID-19. Draft recommendations.
   Google Scholar
• XACT (Factor Xa inhibitor versus standard of care heparin in hospitalized patients with COVID-19). NCT04640181. Available online: https://www.clinicaltrials.gov/ct2/show/NCT04640181. cited 2022 Aug 04.
   Google Scholar
• FREEDOM COVID anticoagulation strategy randomized trial. Available online: https://clinicaltrials.gov/ct2/show/NCT04512079. NCT04512079. cited 06 May, 2022
   Google Scholar
• Efficacy and safety of edoxaban and or colchicine for patients with SARS-CoV-2 infection managed in the Out of Hospital Setting (CONVINCE). Available online: https://clinicaltrials.gov/ct2/show/NCT04516941. NCT04516941. cited 2022 May 10.
   Google Scholar
• Full anticoagulation versus prophylaxis in COVID-19: COALIZAO ACTION trial (ACTION). cited 2022 May 10 Available online. https://clinicaltrials.gov/ct2/show/NCT04394377?term=action&cond=COVID-19&draw=2&rank=3.NCT04394377
   Google Scholar
• Patell R, Bogue T, Koshy A, et al. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood. 2020;136(11):1342–1346.
   Google Scholar
• Giannis D, Allen SL, Davidson A, et al. Thromboembolic outcomes of hospitalized COVID-19 patients in the 90-day post-discharge period: early data from the northwell CORE-19 registry. Blood. 2020;136:33–34.
   Google Scholar
• Ramacciotti E, Barile Agati L, Calderaro D, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet. 2022;399(10319): 50–59.
   Google Scholar
• Spyropoulos AC, Lipardi C, Xu J, et al. Modified IMPROVE VTE risk score and elevated d-dimer identify a high venous thromboembolism risk in acutely ill medical population for extended thromboprophylaxis. TH Open. 2020;4(1):59–65.
   Google Scholar
• Spyropoulos AC, Cohen SL, Gianos E, et al. Validation of the IMPROVE-DD risk assessment model for venous thromboembolism among hospitalized patients with COVID-19. Res Pract Thromb Haemost. 2021;5(2):296–300. 24.
   Google Scholar
• Begic E, Naser N, Begic N, Hypercoagulability in COVID-19 and post-COVID patients - characteristics and current treatment guidelines. EJ Cardiol Pract. 2021;21:2–25. Available online: https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-21/hypercoagulability-in-covid-19-and-post-covid-patients-characteristics-and-cur. Accessed.•European guidelines on antithrombotic therapy in COVID19 patients.•European guidelines on antithrombotic therapy in COVID19 patients
   Google Scholar
• Activ-4c. Available online: https://clinicaltrials.gov/ct2/show/NCT04650087. NCT04650087. cited 2022 May 10.
   Google Scholar
• Hamburg edoxaban for anticoagulation in COVID-19 Study (HERO19). Available online: https://clinicaltrials.gov/ct2/show/NCT04542408. NCT04542408. cited 10 May, 2022
   Google Scholar
• COVID-19 interactions, University of Liverpool. Available online: https://covid19-druginteractions.org/checker. cited 2022 Aug 04.
   Google Scholar
• Unites States Summaries of Product Characteristics. Available online: https://www.accessdata.fda.gov/. cited 2022 Aug 04.
   Google Scholar
• European Summaries of Product Characteristics. Available online: https://www.ema.europa.eu/en. cited 2022 Aug 04.
   Google Scholar
• Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace. 2018;20(8):1231–1242.
   Google Scholar
• Russo V, Bottino R, Rago A, et al. Clinical performance of nonvitamin K antagonist oral anticoagulants in real-world obese patients with atrial fibrillation. Semin Thromb Hemost. 2020;46(8):970–976.
   Google Scholar
• Russo V, Bottino R, Rago A, et al. Atrial fibrillation and malignancy: the clinical performance of non-vitamin K oral anticoagulants-A systematic review. Semin Thromb Hemost. 2019;45(2):205–214.
   Google Scholar
• Russo V, Carbone A, Attena E, et al. clinical benefit of direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic heart valves. Clin Ther. 2019;41(12):2549–2557.
   Google Scholar
• Russo V, Carbone A, Rago A, et al. Direct oral anticoagulants in octogenarians with atrial fibrillation: it is never too late. J Cardiovasc Pharmacol. 2019;73(4):207–214.
   Google Scholar
• Attena E, Albani S, Maraolo AE, et al. Remdesivir-induced bradycardia in COVID-19: a single center prospective study. Circ Arrhythm Electrophysiol. 2021;14(7):e009811.
   Google Scholar
• Russo V, Carbone A, Mottola FF, et al. Effect of triple combination therapy with lopinavir-ritonavir, azithromycin, and hydroxychloroquine on QT interval and arrhythmic risk in hospitalized COVID-19 patients. Front Pharmacol. 2020;11:582348.
   Google Scholar
• Renon F, Rago A, Liccardo B, et al. Direct oral anticoagulants plasma levels measurement: clinical usefulness from trials and real-world data. Semin Thromb Hemost. 2021;47(2):150–160. Epub 2021 Feb 26. PMID: 33636746.
   Google Scholar
• Russo V, Cattaneo D, Giannetti L, et al. Pharmacokinetics of direct oral anticoagulants in patients with atrial fibrillation and extreme obesity. Clin Ther. 2021;43(9):e255–e263.
   Google Scholar